Sugi Predict

Sugi Predict / Compounds / SCHEMBL2607435

SCHEMBL2607435

SCHEMBL2607435

CC(C)c1cncc2ccccc12

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ADRA2A P08913 7/20 0.44
▸ ADRA2B P18089 7/20 0.44
▸ ADRA2C P18825 7/20 0.44
▸ ADRA1A P35348 5/20 0.44
▸ ADRA1D P25100 3/20 0.44
▸ ADRA1B P35368 3/20 0.44
▸ PRKCZ Q05513 1/20 0.42
▸ CYP11B2 P19099 3/20 0.39
▸ CYP1A2 P05177 2/20 0.38
▸ CYP2C9 P11712 2/20 0.38
▸ CYP2C19 P33261 2/20 0.38
▸ CYP11B1 P15538 2/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ CYP2B6 P20813 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ GPR3 P46089 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29875062 1.00 ADRA2A (0.44) ADRA2AADRA2BADRA2CADRA1AADRA1D
SCHEMBL28005982 0.84 CYP1A2 (0.44) ADRA2AADRA2BADRA2CADRA1AADRA1D
SCHEMBL28454494 0.84 PRKCZ (0.43) ADRA2AADRA2BADRA2CADRA1AADRA1D
SCHEMBL20824746 0.84 PRKCZ (0.43) ADRA2AADRA2BADRA2CADRA1AADRA1D
SCHEMBL6176312 0.84 ADRA2A (0.42) ADRA2AADRA2BADRA2CADRA1AADRA1D
SCHEMBL29947549 0.84 ADRA2A (0.42) ADRA2AADRA2BADRA2CADRA1AADRA1D
SCHEMBL30238657 0.84 PRKCZ (0.43) ADRA2AADRA2BADRA2CADRA1AADRA1D
SCHEMBL13509959 0.84 ADRA2A (0.41) ADRA2AADRA2BADRA2CADRA1AADRA1D
SCHEMBL26286605 0.81 TSHR (0.44) ADRA2AADRA2BADRA2CADRA1AADRA1D
SCHEMBL18400234 0.81 TSHR (0.44) ADRA2AADRA2BADRA2CADRA1AADRA1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 465 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239776-A1 AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-07-18 — — US disclosed
US-20240228512-A1 ACYCLIC OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF GENENTECH, INC. (US) 2024-07-11 — — US disclosed
US-20240228512-A1 ACYCLIC OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF GENENTECH, INC. (US) 2024-07-11 — — US disclosed
US-12030878-B2 Substituted indole ether compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2024-07-09 — — US disclosed
US-12030878-B2 Substituted indole ether compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2024-07-09 — — US disclosed
US-20240208967-A1 Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof INVENTISBIO CO LTD (CN) 2024-06-27 — — US disclosed
WO-2024108155-A2 COMPOUNDS, COMPOSITIONS, AND METHODS DENALI THERAPEUTICS INC. (US) 2024-05-23 — — WO disclosed
WO-2024081311-A1 CBL-B MODULATORS AND USES THEREOF NIMBUS CLIO, INC. (US) 2024-04-18 — — WO disclosed
US-20240067638-A1 IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS BRISTOL MYERS SQUIBB CO (US) 2024-02-29 — — US disclosed
US-20240067638-A1 IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS BRISTOL MYERS SQUIBB CO (US) 2024-02-29 — — US disclosed
US-20070274951-A1 Combinations comprising HCV protease inhibitor(s) and HCV polymerase inhibitor(s), and methods of treatment related thereto SCHERING CORPORATION 2007-11-29 — — US disclosed
US-20070237818-A1 Controlled-release formulation of HCV protease inhibitor and methods using the same SCHERING CORPORATION 2007-10-11 — — US disclosed
US-20070232527-A1 Medicaments and methods combining a HCV protease inhibitor and an AKR competitor SCHERING CORPORATION 2007-10-04 — — US disclosed
US-20070232651-A1 Novel anabaseine derivatives, pharmaceutical compositions and methods of use thereof THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH 2007-10-04 — — US disclosed
US-20070207949-A1 Medicaments and methods combining a HCV protease inhibitor and an AKR competitor SCHERING CORPORATION 2007-09-06 — — US disclosed
US-7232912-B2 Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation AGOURON PHARMACEUTICALS, INC. (US) 2007-06-19 — — US disclosed
WO-2007061360-A2 NOVEL 3-BICYCLOCARBONYLAMINOPYRIDINE-2-CARBOXAMIDES OR 3-BICYCLOCARBONYLAMINOPYRAZINE-2-CARBOXAMIDES ASTRAZENECA AB (SE) 2007-05-31 — — WO disclosed
US-20070021351-A1 Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor SCHERING CORPORATION 2007-01-25 — — US disclosed
US-20070010431-A1 Pharmaceutical formulations and methods of treatment using the same SCHERING CORPORATION 2007-01-11 — — US disclosed
US-20070004635-A1 Method of treating interferon non-responders using HCV protease inhibitor SCHERING CORPORATION 2007-01-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004635-A1 Method of treating interferon non-responders using HCV protease inhibitor IFNAR1, IFNG, IRF3 ADRA2A 2011/4885ADRA2B 2016/4885ADRA2C 2396/4885
US-20070232651-A1 Novel anabaseine derivatives, pharmaceutical compositions and methods of use thereof CHRNA7, CHRNA10, CHRNA5 ADRA2A 67/4885ADRA2B 25/4885ADRA2C 43/4885
US-20240208967-A1 Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof EGFR, WEE1, DPYD ADRA2A 4488/4885ADRA2B 3917/4885ADRA2C 4195/4885
US-20070232527-A1 Medicaments and methods combining a HCV protease inhibitor and an AKR competitor CTSV, AKR1B1, AKR1A1 ADRA2A 1964/4885ADRA2B 1894/4885ADRA2C 1790/4885
US-20240239776-A1 AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPL, LPAR1 ADRA2A 476/4885ADRA2B 263/4885ADRA2C 481/4885
US-20240228512-A1 ACYCLIC OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF AZI2, HDAC5, HDAC4 ADRA2A 751/4885ADRA2B 1154/4885ADRA2C 937/4885
US-20070021351-A1 Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor PYGL, SERPINB1, PREP ADRA2A 4648/4885ADRA2B 4543/4885ADRA2C 4304/4885
US-20070274951-A1 Combinations comprising HCV protease inhibitor(s) and HCV polymerase inhibitor(s), and methods of treatment related thereto PREP, CTRL, SERPINB1 ADRA2A 4118/4885ADRA2B 3872/4885ADRA2C 4360/4885
US-20070010431-A1 Pharmaceutical formulations and methods of treatment using the same LPXN, SLC5A11, F12 ADRA2A 562/4885ADRA2B 457/4885ADRA2C 313/4885
US-20240067638-A1 IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS TLR9, TLR1, TLR7 ADRA2A 1918/4885ADRA2B 1625/4885ADRA2C 2516/4885
US-12030878-B2 Substituted indole ether compounds TLR7, TLR8, TLR1 ADRA2A 349/4885ADRA2B 391/4885ADRA2C 370/4885
US-20070207949-A1 Medicaments and methods combining a HCV protease inhibitor and an AKR competitor CTSV, AKR1B1, AKR1A1 ADRA2A 1964/4885ADRA2B 1894/4885ADRA2C 1790/4885
US-20070237818-A1 Controlled-release formulation of HCV protease inhibitor and methods using the same CTRL, PEPD, PRCP ADRA2A 2687/4885ADRA2B 2445/4885ADRA2C 3215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.